Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, October 11, 2026

Back to today

From X

@StableBread

Fajasy on X

Four of BWX Technologies’ $BWXT six top executives took their current roles in 2025, but all four were promoted from inside the company. $BWXT’s 2030 plan depends most on the executives below: → Rex Geveden (President and CEO): CEO since 2017 after joining as COO in 2015. Previously an EVP at Teledyne Technologies $TDY and 17 years at NASA, where he was COO. → Mike Fitzgerald (CFO): CFO since July 2025, interim from May 2025. Joined in 2022 as chief accounting officer; previously at MorganFranklin Consulting and Deloitte. → Joe Miller (President, Government Operations): Since June 2025. Served on the submarine USS Norfolk, joined $BWXT in 2011 as an engineer, and ran Advanced Technologies before taking over the segment. → John MacQuarrie (President, Commercial Operations): More than 28 years at $BWXT, and more than 30 in the nuclear industry. → Kevin McCoy (Chief Nuclear Officer): Moved from Government Operations president in June 2025 to help speed up Columbia- and Virginia-class production. Retired vice admiral and former commander of Naval Sea Systems Command. → Kate Kelly (President, Advanced Technologies): Has run Advanced Technologies, home to Pele, BANR, and TRISO (its microreactor and fuel programs), since June 2025, after joining $BWXT in 2012. Several senior roles turned over in 2025 and 2026: → CFO: Robb LeMasters stepped down in May 2025 and stayed on as a special adviser; Fitzgerald replaced him. → General counsel: Ronald Whitford stepped down on November 4, 2025, and Toby Smith, previously corporate secretary at elevator maker Otis Worldwide $OTIS, replaced him. The 8-K says the exit wasn’t tied to “any legal issue or any disagreement.” → Strategy: Rik Geiersbach, previously head of strategy and corporate development for the defense unit of Boeing $BA, joined as chief strategy officer in September 2025. → Nuclear Operations Group: Retired Rear Admiral Howard Markle now runs the naval reactor plants in place of Gary Camper, with no release announcing the change. $BWXT’s board includes Adm. John Richardson, the former Chief of Naval Operations and former director of Naval Reactors.
@ACapitalLP 1 click

A Capital on X

Two event-driven levered equities I’m thinking about this weekend: $XRX and $SVC. $XRX seems simple on paper. Monetize XFS, delever and unlock substantial equity value. But if it’s that obvious, why hasn’t Icahn’s guy done it in eight years? The recent TPG IP monetization suggests they’re willing to get creative, so what’s preventing an XFS transaction? $SVC is potentially more interesting. If the board accepts TKO’s $2bn hotel portfolio offer, you’re creating the remaining net lease portfolio at a very attractive valuation with significant equity torque from deleveraging. My biggest question is whether TKO actually has the financing commitments to close… Thoughts welcome.
@StableBread

Fajasy on X

85.5% of the BWX Technologies $BWXT stock insiders have sold in the open market since January 2025 came from CEO Rex Geveden. All 14 open-market transactions since then were sales, totaling 129,322 shares and $20.1M. Geveden accounts for 110,625 of the shares and $17.2M, in two phases: 1) Discretionary sales: 45,625 shares at $107.40 on February 26, 2025, and 25,000 at $179.00 on August 6, 2025, both two days after an earnings release and neither under a 10b5-1 plan (a pre-set trading plan). 2) Plan sales: On August 11, 2025, five days after the second sale, he adopted a 10b5-1 plan to sell up to 40,000 shares through August 14, 2026. He sold 10,000 shares/quarter under the plan, at $197.90, $203.26, $204.81, and $172.50, using up all 40,000. He still holds 192,491 shares directly ($28.0M at $145.70). The last two 10-Qs show no new plans adopted in H1 2026, and the Q3 10-Q, due with results on November 2, will show whether he adopted another plan after the first expired. The other eight sales, by seven executives and directors, totaled 18,697 shares and $2.9M. Most of this selling carries little signal. The other insiders’ $2.9M is small, and Geveden’s 40,000 plan shares were scheduled in August 2025. His two discretionary sales matter more. They totaled 70,625 shares ($9.4M) outside any plan, and including the plan sales, he’s sold about a third of his shares since February 2025. But both came right after $BWXT reported earnings, not ahead of them, at $107.40 and $179.00, well below the $238.42 peak. So the selling isn’t a warning sign, but with no insider buying during the drop, insiders aren’t signaling a bottom.

Investor Letters

All letters

Deep Dive: Inter & Co

Inter & Co, Brazil’s second-largest neobank, grew over 20% with controlled delinquencies and 15% book-value compounding while trading at…

INTR $3.3B
Capitalist Letters 7 clicks

A temporary glitch?

Coupang’s November 2025 cybersecurity breach tests whether a selloff is temporary despite its 28% Korean e-commerce share, 14 million-plus…

CPNG $27B
Asian Century Stocks 9 clicks

You Understand Now, Why You Came This Way

Brazil’s October 25 runoff puts Bolsonaro’s likely victory at the center of a bullish regional-stock case; Golar LNG (GLNG) also reports…

GLNG $4.7B
WHAT ARE WE DOING? “Contrarians At The Gate” 3 clicks
SFIX · long

Stitch Fix INC

Stitch Fix’s 2017 IPO rested on overly ambitious long-term growth expectations and an unrealistic definition of its addressable market.

SFIX $370M
Value Investors Club 1 click

CoreWeave, Inc (CRWV)

CoreWeave funds GPU data-center expansion with debt backed by $104 billion in contracted revenue, while GPU cloud rentals generate roughly…

CRWV $43B
SixSigmaCapital: Navigating the Financial Markets 9 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 107

YouTube 4

Blogs 17

Seeking Alpha 49 of 228

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

88 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.